Skip to main content
NCBI home page
Epidemiology and Infection logoLink to Epidemiology and Infection
. 1995 Oct;115(2):315–323. doi: 10.1017/s0950268800058441

Measles vaccine efficacy during an outbreak in a highly vaccinated population: incremental increase in protection with age at vaccination up to 18 months.

G De Serres 1, N Boulianne 1, F Meyer 1, B J Ward 1
PMCID: PMC2271410  PMID: 7589271

Abstract

During a large measles outbreak in Quebec City in 1989, two investigations conducted in parallel evaluated the relative risk of measles and measles vaccine effectiveness with respect to age at vaccination. The study was a school-based case-control study including 563 cases and 1126 classmate controls. The second was a cohort study of the siblings of school cases including 493 siblings aged between 1 and 19 years. The relative risks (RR) of measles were similar in both settings and the trend towards increased vaccine efficacy with increasing age at vaccination was highly significant (P < 0.001). Vaccine efficacy rose from 85% in children vaccinated at 12 months of age to > or = 94% in those vaccinated at 15 months and older. Even for children vaccinated at or after 18 months of age, the RR of measles was reduced when compared with children vaccinated between 15 and 17 months of age (RR 0.61, CI 95% 0.33-1.15). Small changes in the timing of initial measles vaccination can have a major impact on vaccine efficacy.

Full text

PDF
315

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Albrecht P., Ennis F. A., Saltzman E. J., Krugman S. Persistence of maternal antibody in infants beyond 12 months: mechanism of measles vaccine failure. J Pediatr. 1977 Nov;91(5):715–718. doi: 10.1016/s0022-3476(77)81021-4. [DOI] [PubMed] [Google Scholar]
  2. Black F. L. Measles active and passive immunity in a worldwide perspective. Prog Med Virol. 1989;36:1–33. [PubMed] [Google Scholar]
  3. Boulianne N., De Serres G., Duval B., Joly J. R., Meyer F., Déry P., Alary M., Le Hénaff D., Thériault N. Epidémie majeure de rougeole dans la région de Québec malgré une couverture vaccinale de 99%. Can J Public Health. 1991 May-Jun;82(3):189–190. [PubMed] [Google Scholar]
  4. Chen R. T., Markowitz L. E., Albrecht P., Stewart J. A., Mofenson L. M., Preblud S. R., Orenstein W. A. Measles antibody: reevaluation of protective titers. J Infect Dis. 1990 Nov;162(5):1036–1042. doi: 10.1093/infdis/162.5.1036. [DOI] [PubMed] [Google Scholar]
  5. Christenson B., Böttiger M., Heller L. Mass vaccination programme aimed at eradicating measles, mumps, and rubella in Sweden: first experience. Br Med J (Clin Res Ed) 1983 Aug 6;287(6389):389–391. doi: 10.1136/bmj.287.6389.389. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Halloran M. E., Haber M., Longini I. M., Jr Interpretation and estimation of vaccine efficacy under heterogeneity. Am J Epidemiol. 1992 Aug 1;136(3):328–343. doi: 10.1093/oxfordjournals.aje.a116498. [DOI] [PubMed] [Google Scholar]
  7. King G. E., Markowitz L. E., Patriarca P. A., Dales L. G. Clinical efficacy of measles vaccine during the 1990 measles epidemic. Pediatr Infect Dis J. 1991 Dec;10(12):883–888. doi: 10.1097/00006454-199112000-00001. [DOI] [PubMed] [Google Scholar]
  8. Markowitz L. E., Preblud S. R., Fine P. E., Orenstein W. A. Duration of live measles vaccine-induced immunity. Pediatr Infect Dis J. 1990 Feb;9(2):101–110. doi: 10.1097/00006454-199002000-00008. [DOI] [PubMed] [Google Scholar]
  9. Marks J. S., Hayden G. F., Orenstein W. A. Methodologic issues in the evaluation of vaccine effectiveness: measles vaccine at 12 vs. 15 months. Am J Epidemiol. 1982 Sep;116(3):510–523. doi: 10.1093/oxfordjournals.aje.a113435. [DOI] [PubMed] [Google Scholar]
  10. Mast E. E., Berg J. L., Hanrahan L. P., Wassell J. T., Davis J. P. Risk factors for measles in a previously vaccinated population and cost-effectiveness of revaccination strategies. JAMA. 1990 Nov 21;264(19):2529–2533. [PubMed] [Google Scholar]
  11. McLean M. E., Walsh P. J., Carter A. O., Lavigne P. M. Measles in Canada-1989. Can Dis Wkly Rep. 1990 Oct 20;16(42):213–218. [PubMed] [Google Scholar]
  12. Miettinen O. Estimability and estimation in case-referent studies. Am J Epidemiol. 1976 Feb;103(2):226–235. doi: 10.1093/oxfordjournals.aje.a112220. [DOI] [PubMed] [Google Scholar]
  13. Orenstein W. A., Bernier R. H., Hinman A. R. Assessing vaccine efficacy in the field. Further observations. Epidemiol Rev. 1988;10:212–241. doi: 10.1093/oxfordjournals.epirev.a036023. [DOI] [PubMed] [Google Scholar]
  14. Orenstein W. A., Markowitz L., Preblud S. R., Hinman A. R., Tomasi A., Bart K. J. Appropriate age for measles vaccination in the United States. Dev Biol Stand. 1986;65:13–21. [PubMed] [Google Scholar]
  15. Rosenthal S. R., Clements C. J. Two-dose measles vaccination schedules. Bull World Health Organ. 1993;71(3-4):421–428. [PMC free article] [PubMed] [Google Scholar]
  16. Wilkins J., Wehrle P. F. Evidence for reinstatement of infants 12 to 14 months of age into routine measles immunization programs. Am J Dis Child. 1978 Feb;132(2):164–166. doi: 10.1001/archpedi.1978.02120270062013. [DOI] [PubMed] [Google Scholar]
  17. Wong T., Lee-Han H., Bell B., Daley J., Bailey N., Vanderpol M. Measles epidemic in Waterloo region, Ontario, 1990-1991. Can Dis Wkly Rep. 1991 Oct 12;17(41):219–224. [PubMed] [Google Scholar]
  18. Yuan L. Measles outbreak in 31 schools: risk factors for vaccine failure and evaluation of a selective revaccination strategy. CMAJ. 1994 Apr 1;150(7):1093–1098. [PMC free article] [PubMed] [Google Scholar]

Articles from Epidemiology and Infection are provided here courtesy of Cambridge University Press

RESOURCES